Muscle & Bone Health After 40

Abstract

Osteosarcopenia is now recognised as one of the most clinically significant musculoskeletal conditions of ageing. Both sarcopenia and osteoporosis share common pathophysiological roots: declining levels of anabolic hormones (including oestrogen,- testosterone and insulin-like growth factor-1), rising systemic inflammation driven by pro-inflammatory cytokines such as interleukin- 6 and tumour necrosis factor-alpha, impaired mitochondrial function, and deteriorating nutritional status. When muscle mass declines, the mechanical stimulation of bone is reduced, accelerating bone loss and conversely, reduced bone quality impairs the structural framework that supports muscular attachment and function. This interplay means that addressing bone and muscle health in isolation is scientifically inadequate; they must be approached as a unified biological system. The five main pathological processes driving bone and muscle loss after 40 are: (1) declining anabolic hormone signaling [addressed by boron and zinc]; (2) rising inflammatory cytokines [addressed by vitamin D, C, and magnesium]; (3) declining collagen synthesis [addressed by ch-OSA and vitamin C]; (4) impaired calcium regulation [addressed by vitamin D, K2, and magnesium]; (5) elevated homocysteine [addressed by B12 and B1]. This formulation addresses all five pathways.